Copyright Reports & Markets. All rights reserved.

Global Pulmonary Arterial Hypertension (PAH) Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Pulmonary Arterial Hypertension (PAH) Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate by Product
      • 1.4.2 Prostacyclin and Prostacyclin Analogs
      • 1.4.3 SGC Stimulators
      • 1.4.4 ERA
      • 1.4.5 PDE-5
    • 1.5 Market by End User
      • 1.5.1 Global Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 Clinic
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Pulmonary Arterial Hypertension (PAH) Market Size
      • 2.1.1 Global Pulmonary Arterial Hypertension (PAH) Revenue 2014-2025
      • 2.1.2 Global Pulmonary Arterial Hypertension (PAH) Sales 2014-2025
    • 2.2 Pulmonary Arterial Hypertension (PAH) Growth Rate by Regions
      • 2.2.1 Global Pulmonary Arterial Hypertension (PAH) Sales by Regions
      • 2.2.2 Global Pulmonary Arterial Hypertension (PAH) Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Pulmonary Arterial Hypertension (PAH) Sales by Manufacturers
      • 3.1.1 Pulmonary Arterial Hypertension (PAH) Sales by Manufacturers
      • 3.1.2 Pulmonary Arterial Hypertension (PAH) Sales Market Share by Manufacturers
      • 3.1.3 Global Pulmonary Arterial Hypertension (PAH) Market Concentration Ratio (CR5 and HHI)
    • 3.2 Pulmonary Arterial Hypertension (PAH) Revenue by Manufacturers
      • 3.2.1 Pulmonary Arterial Hypertension (PAH) Revenue by Manufacturers (2014-2019)
      • 3.2.2 Pulmonary Arterial Hypertension (PAH) Revenue Share by Manufacturers (2014-2019)
    • 3.3 Pulmonary Arterial Hypertension (PAH) Price by Manufacturers
    • 3.4 Pulmonary Arterial Hypertension (PAH) Manufacturing Base Distribution, Product Types
      • 3.4.1 Pulmonary Arterial Hypertension (PAH) Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Pulmonary Arterial Hypertension (PAH) Product Type
      • 3.4.3 Date of International Manufacturers Enter into Pulmonary Arterial Hypertension (PAH) Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Pulmonary Arterial Hypertension (PAH) Sales by Product
    • 4.2 Global Pulmonary Arterial Hypertension (PAH) Revenue by Product
    • 4.3 Pulmonary Arterial Hypertension (PAH) Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Pulmonary Arterial Hypertension (PAH) Breakdown Data by End User

    6 North America

    • 6.1 North America Pulmonary Arterial Hypertension (PAH) by Countries
      • 6.1.1 North America Pulmonary Arterial Hypertension (PAH) Sales by Countries
      • 6.1.2 North America Pulmonary Arterial Hypertension (PAH) Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Pulmonary Arterial Hypertension (PAH) by Product
    • 6.3 North America Pulmonary Arterial Hypertension (PAH) by End User

    7 Europe

    • 7.1 Europe Pulmonary Arterial Hypertension (PAH) by Countries
      • 7.1.1 Europe Pulmonary Arterial Hypertension (PAH) Sales by Countries
      • 7.1.2 Europe Pulmonary Arterial Hypertension (PAH) Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Pulmonary Arterial Hypertension (PAH) by Product
    • 7.3 Europe Pulmonary Arterial Hypertension (PAH) by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Pulmonary Arterial Hypertension (PAH) by Countries
      • 8.1.1 Asia Pacific Pulmonary Arterial Hypertension (PAH) Sales by Countries
      • 8.1.2 Asia Pacific Pulmonary Arterial Hypertension (PAH) Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Pulmonary Arterial Hypertension (PAH) by Product
    • 8.3 Asia Pacific Pulmonary Arterial Hypertension (PAH) by End User

    9 Central & South America

    • 9.1 Central & South America Pulmonary Arterial Hypertension (PAH) by Countries
      • 9.1.1 Central & South America Pulmonary Arterial Hypertension (PAH) Sales by Countries
      • 9.1.2 Central & South America Pulmonary Arterial Hypertension (PAH) Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Pulmonary Arterial Hypertension (PAH) by Product
    • 9.3 Central & South America Pulmonary Arterial Hypertension (PAH) by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) by Countries
      • 10.1.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Sales by Countries
      • 10.1.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) by Product
    • 10.3 Middle East and Africa Pulmonary Arterial Hypertension (PAH) by End User

    11 Company Profiles

    • 11.1 Actelion
      • 11.1.1 Actelion Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Actelion Pulmonary Arterial Hypertension (PAH) Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Actelion Pulmonary Arterial Hypertension (PAH) Products Offered
      • 11.1.5 Actelion Recent Development
    • 11.2 Gilead Sciences
      • 11.2.1 Gilead Sciences Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Products Offered
      • 11.2.5 Gilead Sciences Recent Development
    • 11.3 United Therapeutics
      • 11.3.1 United Therapeutics Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 United Therapeutics Pulmonary Arterial Hypertension (PAH) Products Offered
      • 11.3.5 United Therapeutics Recent Development
    • 11.4 GlaxoSmithKline
      • 11.4.1 GlaxoSmithKline Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Products Offered
      • 11.4.5 GlaxoSmithKline Recent Development
    • 11.5 Pfizer
      • 11.5.1 Pfizer Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Pfizer Pulmonary Arterial Hypertension (PAH) Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Pfizer Pulmonary Arterial Hypertension (PAH) Products Offered
      • 11.5.5 Pfizer Recent Development
    • 11.6 Bayer
      • 11.6.1 Bayer Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Bayer Pulmonary Arterial Hypertension (PAH) Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Bayer Pulmonary Arterial Hypertension (PAH) Products Offered
      • 11.6.5 Bayer Recent Development
    • 11.7 Arena
      • 11.7.1 Arena Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Arena Pulmonary Arterial Hypertension (PAH) Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Arena Pulmonary Arterial Hypertension (PAH) Products Offered
      • 11.7.5 Arena Recent Development

    12 Future Forecast

    • 12.1 Pulmonary Arterial Hypertension (PAH) Market Forecast by Regions
      • 12.1.1 Global Pulmonary Arterial Hypertension (PAH) Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Pulmonary Arterial Hypertension (PAH) Revenue Forecast by Regions 2019-2025
    • 12.2 Pulmonary Arterial Hypertension (PAH) Market Forecast by Product
      • 12.2.1 Global Pulmonary Arterial Hypertension (PAH) Sales Forecast by Product 2019-2025
      • 12.2.2 Global Pulmonary Arterial Hypertension (PAH) Revenue Forecast by Product 2019-2025
    • 12.3 Pulmonary Arterial Hypertension (PAH) Market Forecast by End User
    • 12.4 North America Pulmonary Arterial Hypertension (PAH) Forecast
    • 12.5 Europe Pulmonary Arterial Hypertension (PAH) Forecast
    • 12.6 Asia Pacific Pulmonary Arterial Hypertension (PAH) Forecast
    • 12.7 Central & South America Pulmonary Arterial Hypertension (PAH) Forecast
    • 12.8 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Pulmonary Arterial Hypertension (PAH) Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Pulmonary hypertension is a condition of increased blood pressure within the arteries of the lungs.[6] Symptoms include shortness of breath, syncope, tiredness, chest pain, swelling of the legs, and a fast heartbeat.
      The global Pulmonary Arterial Hypertension (PAH) market is valued at 5960 million US$ in 2018 and will reach 9970 million US$ by the end of 2025, growing at a CAGR of 6.7% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Pulmonary Arterial Hypertension (PAH) market based on company, product type, end user and key regions.

      This report studies the global market size of Pulmonary Arterial Hypertension (PAH) in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Pulmonary Arterial Hypertension (PAH) in these regions.
      This research report categorizes the global Pulmonary Arterial Hypertension (PAH) market by top players/brands, region, type and end user. This report also studies the global Pulmonary Arterial Hypertension (PAH) market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Actelion
      Gilead Sciences
      United Therapeutics
      GlaxoSmithKline
      Pfizer
      Bayer
      Arena

      Market size by Product
      Prostacyclin and Prostacyclin Analogs
      SGC Stimulators
      ERA
      PDE-5
      Market size by End User
      Hospital
      Clinic

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Pulmonary Arterial Hypertension (PAH) market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Pulmonary Arterial Hypertension (PAH) market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Pulmonary Arterial Hypertension (PAH) companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Pulmonary Arterial Hypertension (PAH) submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Pulmonary Arterial Hypertension (PAH) are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Pulmonary Arterial Hypertension (PAH) market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now